Last updated on July 2020

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection


Brief description of study

Summit is developing ridinilazole as a novel antimicrobial for Clostridium difficile Infection (CDI) with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease.

A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these attributes with a comparable safety profile. A high fecal concentration of ridinilazole and little systemic exposure were noted.

The rationale for this phase 3 study is to confirm the improvement in sustained clinical response of CDI over vancomycin and to compare the safety and tolerability of ridinilazole to that of vancomycin.

Clinical Study Identifier: NCT03595553

Find a site near you

Start Over

William Beaumont Hospital

Royal Oak, MI United States
1.83miles
  Connect »

Revival Research Institute, LLC.

Southfield, MI United States
5.23miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.